Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBIT Margin (2019 - 2025)

Historic EBIT Margin for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to 32.39%.

  • Biodesix's EBIT Margin rose 149400.0% to 32.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.61%, marking a year-over-year increase of 123500.0%. This contributed to the annual value of 48.37% for FY2024, which is 358500.0% up from last year.
  • Per Biodesix's latest filing, its EBIT Margin stood at 32.39% for Q3 2025, which was up 149400.0% from 48.55% recorded in Q2 2025.
  • In the past 5 years, Biodesix's EBIT Margin ranged from a high of 19.34% in Q1 2021 and a low of 220.85% during Q1 2022
  • In the last 5 years, Biodesix's EBIT Margin had a median value of 74.38% in 2024 and averaged 91.71%.
  • In the last 5 years, Biodesix's EBIT Margin skyrocketed by 1459300bps in 2021 and then plummeted by -2015000bps in 2022.
  • Over the past 5 years, Biodesix's EBIT Margin (Quarter) stood at 161.67% in 2021, then increased by 11bps to 144.58% in 2022, then surged by 68bps to 46.84% in 2023, then surged by 31bps to 32.55% in 2024, then increased by 0bps to 32.39% in 2025.
  • Its EBIT Margin was 32.39% in Q3 2025, compared to 48.55% in Q2 2025 and 50.87% in Q1 2025.